PURPOSE: The aim of this study was to systematically review and conduct a meta-analysis of published data about the diagnostic performance of (18)F-dihydroxyphenylalanine (DOPA) positron emission tomography (PET) in patients with paraganglioma (PG). METHODS: A comprehensive computer literature search of studies published through 30 June 2011 regarding (18)F-DOPA PET or PET/computed tomography (PET/CT) in patients with PG was performed in PubMed/MEDLINE, Embase and Scopus databases. Pooled sensitivity and specificity of (18)F-DOPA PET or PET/CT in patients with PG on a per patient- and on a per lesion-based analysis were calculated. The area under the receiver-operating characteristic (ROC) curve was calculated to measure the accuracy of (18)F-DOPA PET or PET/CT in patients with PG. Furthermore, a sub-analysis taking into account the different genetic mutations in PG patients was also performed. RESULTS: Eleven studies comprising 275 patients with suspected PG were included in this meta-analysis. The pooled sensitivity of (18)F-DOPA PET and PET/CT in detecting PG was 91% [95% confidence interval (CI) 87-94%] on a per patient-based analysis and 79% (95% CI 76-81%) on a per lesion-based analysis. The pooled specificity of (18)F-DOPA PET and PET/CT in detecting PG was 95% (95% CI 86-99%) on a per patient-based analysis and 95% (95% CI 84-99%) on a per lesion-based analysis. The area under the ROC curve was 0.95 on a per patient- and 0.94 on a per lesion-based analysis. Heterogeneity between the studies about sensitivity of (18)F-DOPA PET or PET/CT was found. A significant increase in sensitivity of (18)F-DOPA PET or PET/CT was observed when a sub-analysis excluding patients with succinate dehydrogenase subunit B (SDHB) gene mutations was performed. CONCLUSION: In patients with suspected PG (18)F-DOPA PET or PET/CT demonstrated high sensitivity and specificity. (18)F-DOPA PET or PET/CT are accurate methods in this setting. Nevertheless, possible sources of false-negative results should be kept in mind. Furthermore, SDHB gene mutations could influence (18)F-DOPA PET or PET/CT diagnostic performance.
PURPOSE: The aim of this study was to systematically review and conduct a meta-analysis of published data about the diagnostic performance of (18)F-dihydroxyphenylalanine (DOPA) positron emission tomography (PET) in patients with paraganglioma (PG). METHODS: A comprehensive computer literature search of studies published through 30 June 2011 regarding (18)F-DOPA PET or PET/computed tomography (PET/CT) in patients with PG was performed in PubMed/MEDLINE, Embase and Scopus databases. Pooled sensitivity and specificity of (18)F-DOPA PET or PET/CT in patients with PG on a per patient- and on a per lesion-based analysis were calculated. The area under the receiver-operating characteristic (ROC) curve was calculated to measure the accuracy of (18)F-DOPA PET or PET/CT in patients with PG. Furthermore, a sub-analysis taking into account the different genetic mutations in PG patients was also performed. RESULTS: Eleven studies comprising 275 patients with suspected PG were included in this meta-analysis. The pooled sensitivity of (18)F-DOPA PET and PET/CT in detecting PG was 91% [95% confidence interval (CI) 87-94%] on a per patient-based analysis and 79% (95% CI 76-81%) on a per lesion-based analysis. The pooled specificity of (18)F-DOPA PET and PET/CT in detecting PG was 95% (95% CI 86-99%) on a per patient-based analysis and 95% (95% CI 84-99%) on a per lesion-based analysis. The area under the ROC curve was 0.95 on a per patient- and 0.94 on a per lesion-based analysis. Heterogeneity between the studies about sensitivity of (18)F-DOPA PET or PET/CT was found. A significant increase in sensitivity of (18)F-DOPA PET or PET/CT was observed when a sub-analysis excluding patients with succinate dehydrogenase subunit B (SDHB) gene mutations was performed. CONCLUSION: In patients with suspected PG (18)F-DOPA PET or PET/CT demonstrated high sensitivity and specificity. (18)F-DOPA PET or PET/CT are accurate methods in this setting. Nevertheless, possible sources of false-negative results should be kept in mind. Furthermore, SDHB gene mutations could influence (18)F-DOPA PET or PET/CT diagnostic performance.
Authors: Helle-Brit Fiebrich; Adrienne H Brouwers; Leo van Bergeijk; Gerrit van den Berg Journal: J Clin Endocrinol Metab Date: 2009-03 Impact factor: 5.958
Authors: Henri J L M Timmers; Mohiuddin Hadi; Jorge A Carrasquillo; Clara C Chen; Lucia Martiniova; Millie Whatley; Alexander Ling; Graeme Eisenhofer; Karen T Adams; Karel Pacak Journal: J Nucl Med Date: 2007-09-14 Impact factor: 10.057
Authors: Helle-Brit Fiebrich; Adrienne H Brouwers; Michiel N Kerstens; Milan E J Pijl; Ido P Kema; Johan R de Jong; Pieter L Jager; Philip H Elsinga; Rudi A J O Dierckx; Jacqueline E van der Wal; Wim J Sluiter; Elisabeth G E de Vries; Thera P Links Journal: J Clin Endocrinol Metab Date: 2009-07-21 Impact factor: 5.958
Authors: Markus Luster; Wolfram Karges; Katrin Zeich; Sandra Pauls; Frederik A Verburg; Henning Dralle; Gerhard Glatting; Andreas K Buck; Christoph Solbach; Bernd Neumaier; Sven N Reske; Felix M Mottaghy Journal: Eur J Nucl Med Mol Imaging Date: 2009-10-28 Impact factor: 9.236
Authors: Bas Havekes; Kathryn King; Edwin W Lai; Johannes A Romijn; Eleonora P M Corssmit; Karel Pacak Journal: Clin Endocrinol (Oxf) Date: 2009-06-08 Impact factor: 3.478
Authors: Penny F Whiting; Marie E Weswood; Anne W S Rutjes; Johannes B Reitsma; Patrick N M Bossuyt; Jos Kleijnen Journal: BMC Med Res Methodol Date: 2006-03-06 Impact factor: 4.615
Authors: Sophie Gabriel; Elise M Blanchet; Frédéric Sebag; Clara C Chen; Nicolas Fakhry; Arnaud Deveze; Anne Barlier; Isabelle Morange; Karel Pacak; David Taïeb Journal: Clin Endocrinol (Oxf) Date: 2013-05-06 Impact factor: 3.478
Authors: Elise M Blanchet; Corina Millo; Victoria Martucci; Roberto Maass-Moreno; David A Bluemke; Karel Pacak Journal: Clin Nucl Med Date: 2014-03 Impact factor: 7.794
Authors: Chloé C Feral; Floriane S Tissot; Lionel Tosello; Nicolas Fakhry; Fréderic Sebag; Karel Pacak; David Taïeb Journal: Eur J Nucl Med Mol Imaging Date: 2016-11-29 Impact factor: 9.236
Authors: Karel Pacak; David Taïeb; Elise M Blanchet; Sophie Gabriel; Victoria Martucci; Nicolas Fakhry; Clara C Chen; Arnaud Deveze; Corina Millo; Anne Barlier; Morgane Pertuit; Anderson Loundou Journal: Eur J Clin Invest Date: 2014 Impact factor: 4.686